Advances in Therapy

, Volume 22, Issue 6, pp 578–586 | Cite as

Hepatitis A: A preventable threat

  • Alexander K. C. Leung
  • James D. Kellner
  • H. Dele Davies


Hepatitis A is a major public health problem, particularly in the pediatric population. Although hepatitis A infection does not cause chronic liver disease, it is associated with significant morbidity. The virus is transmitted primarily by person-to-person contact via the fecal-oral route. The infection can be inapparent, subclinical, anicteric, or icteric. In general, the severity of the disease is inversely correlated with the age of the child. Occasionally, fulminant hepatitis, which is associated with a high mortality rate, may result. The diagnosis of acute hepatitis A is most commonly made through the detection of immunoglobulin M (IgM) anti-hepatitis A antibody. Treatment is generally supportive. General preventive measures include improved standards of hygiene and sanitation. Universal childhood vaccination is the most effective method for eradicating hepatitis A and preventing its transmission.


hepatitis A morbidity transmission vaccination 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Steele RW. Hepatitis A vaccine: time for universal immunization.Clin Pediatr. 2002;41:1–3.CrossRefGoogle Scholar
  2. 2.
    Lee A, Cheng F, Lau L, et al. Should adolescents be vaccinated against hepatitis A: the Hong Kong experience.Vaccine. 2000;18:941–946.CrossRefGoogle Scholar
  3. 3.
    Rosenthal P. Cost-effectiveness of hepatitis A vaccination in children, adolescents, and adults.Hepatology. 2003;37:44–51.PubMedCrossRefGoogle Scholar
  4. 4.
    Bell BP, Shapiro CN. Hepatitis A virus. In: Long SS, Pickering LK, Prober CG, eds.Principles and Practice of Pediatric Infectious Diseases. New York, NY: Churchill Livingstone; 2003:1188–1192.Google Scholar
  5. 5.
    Curry MP, Chopra S. Acute viral hepatitis. In: Mandell GL, Bennett JE, Dolin R, eds.Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. Philadelphia, Pa: Elsevier Churchill Livingstone; 2005:1426–1441.Google Scholar
  6. 6.
    American Academy of Pediatrics. Hepatitis A. In: Pickering LK, ed.Red Book: 2003 Report of the Committee on Infectious Diseases. Elk Grove Village, Ill: American Academy of Pediatrics; 2003:309–318.Google Scholar
  7. 7.
    Kemmer NM, Miskovsky EP. Hepatitis A.Infect Dis Clin North Am. 2000;14:605–615.PubMedCrossRefGoogle Scholar
  8. 8.
    MacIntyre CR, Burgess MA, Hull B, et al. Hepatitis A vaccination options for Australia.J Paediatr Child Health. 2003;39:83–87.PubMedCrossRefGoogle Scholar
  9. 9.
    Fiore AE. Hepatitis A transmission by food.Clin Infect Dis. 2004;38:705–715.PubMedCrossRefGoogle Scholar
  10. 10.
    Leikin E, Lysikiewicz A, Garry D, et al. Intrauterine transmission of hepatitis A virus.Obstet Gynecol. 1996;88:690–691.PubMedCrossRefGoogle Scholar
  11. 11.
    Crowcroft NS, Walsh B, Davison KL, et al. Guidelines for the control of hepatitis A virus infection.Commun Dis Public Health. 2001;4:213–227.PubMedGoogle Scholar
  12. 12.
    Bonanni P, Franzin A, Staderini C, et al. Vaccination against hepatitis A during outbreaks starting in schools: what can we learn from experiences in central Italy?Vaccine. 2005;23:2176–2180.PubMedCrossRefGoogle Scholar
  13. 13.
    Hochman JA, Balistreri WF. Viral hepatitis: expanding the alphabet.Adv Pediatr. 1999;46:207–243.PubMedGoogle Scholar
  14. 14.
    Gonzalez-Peralta RP, Jolley C. Hepatitis A. In: Rudolph CD, Rudolph AM, Hostetter MK, et al, eds.Rudolph’s Pediatrics. New York, NY: McGraw-Hill; 2003:1495–1497.Google Scholar
  15. 15.
    Glikson M, Galun E, Oren R, et al. Replacing hepatitis A: review of 14 cases and literature survey.Medicine. 1992;71:14–23.PubMedGoogle Scholar
  16. 16.
    Tong MJ, El-Farra NS, Grew MI. Clinical manifestations of hepatitis A: recent experience in a community teaching hospital.J Infect Dis. 1995;171(suppl 1):15–18.Google Scholar
  17. 17.
    Schiff ER. Atypical clinical manifestations of hepatitis A.Vaccine. 1992;10(suppl 1):18–20.CrossRefGoogle Scholar
  18. 18.
    Rachaman SM, Chira P, Koff RS. Idiopathic autoimmune chronic hepatitis triggered by hepatitis A.Am J Gastroenterol. 1994;89:106–108.Google Scholar
  19. 19.
    Vento S, Garofano T, Di Pierri G, et al. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals.Lancet. 1991;337:1183–1187.PubMedCrossRefGoogle Scholar
  20. 20.
    Ertem D, Acar Y, Pehlivanoglu E. Autoimmune complications associated with hepatitis A virus infection in children.Pediatr Infect Dis J. 2001;20:809–811.PubMedGoogle Scholar
  21. 21.
    Yende S, Lancaster D. Hepatitis A: a potentially serious disease.Ann Intern Med. 1998;128:111–114.Google Scholar
  22. 22.
    Bell BP, Anderson DA, Feinstone SM. Hepatitis A virus. In: Mandell GL, Bennett JE, Dolin R, eds.Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. Philadelphia, Pa: Elsevier Churchill Livingstone; 2005:2162–2185.Google Scholar
  23. 23.
    Robson WL, Leung AK. Nephrotic syndrome in childhood.Adv Pediatr. 1993;40:287–323.PubMedGoogle Scholar
  24. 24.
    Tan H, Kiliçaslan B, Önbas O, et al. Acute disseminated encephalomyelitis following hepatitis A virus infection.Pediatr Neurol. 2004;30:207–209.PubMedCrossRefGoogle Scholar
  25. 25.
    Ilan Y, Hillman M, Oren R, et al. Vasculitis and cryoglobulinemia associated with persisting cholestatic hepatitis A virus infection.Am J Gastroenterol. 1990;85:586–587.PubMedGoogle Scholar
  26. 26.
    Pickering LK. Viral hepatitis. In: Behrman RE, Kliegman RM, Jenson HB, eds.Nelson Textbook of Pediatrics. Philadelphia, Pa: WB Saunders Co.; 2003:1324–1327.Google Scholar
  27. 27.
    Tanuos H. Hepatitis A.Pediatr Rev. 1999;20:102.PubMedCrossRefGoogle Scholar
  28. 28.
    Crance JM, Biziagos E, Passagot J, et al. Inhibition of hepatitis A virus replication in vitro by antiviral compounds.J Med Virol. 1990;31:155–160.PubMedCrossRefGoogle Scholar
  29. 29.
    Sinclair SB, Levy GA. Treatment of fulminant viral hepatic failure with prostaglandin E: a preliminary report.Dig Dis Sci. 1991;36:791–800.PubMedCrossRefGoogle Scholar
  30. 30.
    Schiodt FV, Atillasoy E, Shakil AO, et al. Etiology and outcome for 295 patients with liver failure in the United States.Liver Transpl Surg. 1999;5:29–34.PubMedCrossRefGoogle Scholar
  31. 31.
    Averhoff F, Shapiro CN, Bell BP. Control of hepatitis A through routine vaccination of children.JAMA. 2001;286:2968–2973.PubMedCrossRefGoogle Scholar
  32. 32.
    Clemens R, Safary A, Hepburn A, et al. Clinical experience with an inactivated hepatitis A vaccine.J Infect Dis. 1995;171(suppl 1):S44-S49.PubMedGoogle Scholar
  33. 33.
    Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWR Recomm Rep. 1999;48(RR-12):1–37.Google Scholar
  34. 34.
    Landry P, Tremblay S, Darioli R. Inactivated hepatitis A vaccine booster dose given ≥24 months after the primary dose.Vaccine. 2001;19:399–402.CrossRefGoogle Scholar
  35. 35.
    Bryan JP, Henry CH, Hoffman AG, et al. Randomized, cross-over controlled comparison of two inactivated hepatitis A vaccines.Vaccine. 2000;19:743–750.PubMedCrossRefGoogle Scholar
  36. 36.
    Connor BA, Phair J, Sack D, et al. Randomized double-blind study in healthy adults to assess the boosting effect of VAQTA® or HAVRIX® after a single dose of HAVRIX®.Clin Infect Dis. 2001;34:396–401.CrossRefGoogle Scholar
  37. 37.
    Wiens BL, Bohidar NR, Pigeon JG, et al. Duration of protection from clinical hepatitis A disease after vaccination with VAQTA.J Med Virol. 1996;49:235–241.PubMedCrossRefGoogle Scholar
  38. 38.
    Ashur Y, Adler R, Rowe M, et al. Comparison of immunogenicity of two hepatitis A vaccines-Vaqta and Havrix—in young adults.Vaccine. 1999;17:2290–2296.PubMedCrossRefGoogle Scholar
  39. 39.
    van Damme P, Banatvala J, Fay O, et al. Hepatitis A booster vaccination: is there a need?Lancet. 2003;362:1065–1071.PubMedCrossRefGoogle Scholar
  40. 40.
    Kanra G, Yalçin SS, Kara A, et al. Hepatitis A booster vaccine in children after infant immunization.Pediatr Infect Dis J. 2002;21:727–730.PubMedCrossRefGoogle Scholar
  41. 41.
    Piazza M, Safary A, Vegnente A, et al. Safety and immunogenicity of hepatitis A vaccine in infants: a candidate for inclusion in the childhood vaccination programme.Vaccine. 1999;17: 585–588.PubMedCrossRefGoogle Scholar
  42. 42.
    Dagan R, Amir J, Mijalovsky A, et al. Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody.Pediatr Infect Dis J. 2000;19:1045–1052.PubMedCrossRefGoogle Scholar
  43. 43.
    Fiore AE, Shapiro CN, Sabin K, et al. Hepatitis A vaccination of infants: effect of maternal antibody status on antibody persistence and response to a booster dose.Pediatr Infect Dis J. 2003;22: 354–359.PubMedCrossRefGoogle Scholar
  44. 44.
    Black S, Shinefield H, Hansen J, et al. A post-licensure evaluation of the safety of inactivated hepatitis A vaccine (VAQTA®, Merck) in children and adults.Vaccine. 2004;22:766–772.PubMedCrossRefGoogle Scholar
  45. 45.
    Zimmerman RK, Middleton DB, Burns LT, et al. Routine vaccines across the life span, 2005.J Fam Pract. 2005;54:S9-S26.PubMedGoogle Scholar
  46. 46.
    Centers for Disease Control and Prevention. Recommended childhood immunization schedule: United States.MMWR Morb Mortal Wkly Rep. 2001;50:7–10, 19.Google Scholar
  47. 47.
    Webster G, Barnes E, Dushieiko G. Protecting travellers from hepatitis A.BMJ. 2001;322:1194–1195.PubMedCrossRefGoogle Scholar
  48. 48.
    Sagliocca L, Amoroso P, Stroffolini T, et al. Efficacy of hepatitis A vaccine in prevention of secondary hepatitis A infection: a randomised trial.Lancet. 1999;353:1136–1139.PubMedCrossRefGoogle Scholar
  49. 49.
    Péchevis M, Khoshnood B, Buteau L, et al. Cost-effectiveness of hepatitis A vaccine in prevention of secondary hepatitis A infection.Vaccine. 2003;21:3556–3564.PubMedCrossRefGoogle Scholar
  50. 50.
    Armstrong GL, Bell BP. Hepatitis A infections in the United States: model-based estimates and implications for childhood immunization.Pediatrics. 2002;109:839–845.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science and Business Media and LLC 2005

Authors and Affiliations

  • Alexander K. C. Leung
    • 1
  • James D. Kellner
    • 1
  • H. Dele Davies
    • 2
  1. 1.Department of PediatricsUniversity of Calgary Alberta Children’s Hospital CalgaryAlbertaCanada
  2. 2.Department of Pediatrics and Human Development MichiganState UniversityEast Lansing

Personalised recommendations